After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
The same trial that sent Summit up 272% sees the stock crash 36%.
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
